【摘要】 目的观察并初步探讨二肽基肽酶4(Dipeptidyl peptidase 4,DPP4)抑制剂西格列汀联合二甲双胍治疗2型糖尿病的临床疗效。方法选择2014年1月至2015年2月来我院就诊的63例2型糖尿病患者作为研究对象,随机分为3组。对照组单一给药二甲双胍(A组)、西格列汀(Sitagliptin)(B组),观察组(C组)给予西格列汀联合二甲双胍治疗,治疗12周后检测并观察各组总体疗效及相关生化指标。结果 C组治疗后空腹血糖(FBG)、餐后2小时血糖(2h BG)分别为(7.4±1.7)、(8.2±1.9)mmol/L,与A组、B组相比显著降低,差异有统计学意义(P<0.05)。C组糖化血红蛋白(Hb A1c)、体重指数(BMI)及血尿酸(UA)均较A组、B组呈下降趋势,但差异无统计学意义(P>0.05)。结论 DPP4抑制剂西格列汀联合二甲双胍治疗2型糖尿病疗效显著,能够全面控制血糖,降低体重,降低血尿酸,不增加低血糖的发生,具有良好的安全耐受性,值得临床应用推广。更多还原

【Abstract】 Objective To investigate the effects of dipeptidyl peptidase 4 inhibitor(sitag liptin) combined with metformin in the treatment of patients with type 2 diabetes mellitus.Methods Totally 63 cases of type 2 diabetes in our hospital from January 2014 to February 2015 were selected and randomly divided into three groups:control group(group A,group B) was given single use of metformin(group A) or sitagliptin(group B);observation group(group C) was given metformin combined with sitagliptin.Biochemical indicator was determined,and overall curative effect was observed after 12 weeks of treatment.Results The fasting blood glucose and 2-hour postprandial blood glucose of group C was(7.4 ± 1.7) and(8.2 ± 1.9) mmol / L respectively,which was lower than that of group A and group B(P < 0.05).The levels of glycated hemoglobin blood(Hb A1c),body mass index(BMI) and uric acid(UA) of group C were slightly lower than those of group A and group B,but there was no significant difference(P > 0.05).Conclusion Sitagliptin combined with metformin has significant curative effect in the treatment of type 2 diabetes mellitus,which can control diabetes generally,reduce body weight and decrease the serum UA levels with a good safety and tolerance.It is worth using in clinical practice.更多还原